Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma

Biomark Med. 2022 Apr;16(6):435-448. doi: 10.2217/bmm-2021-1051. Epub 2022 Feb 25.

Abstract

Background: Hypoxia and immunosuppression are two properties of cancer. This study intends to establish the potential relationship between these two hallmarks in hepatocellular carcinoma (HCC). Materials & methods: A bioinformatics analysis of data obtained from the Cancer Genome Atlas and a retrospective single-center analysis based on a tissue microarray were utilized in this study. Results: We identified a hypoxia-high subtype of patients with immunosuppressive HCC which represented a poor prognosis in the Cancer Genome Atlas cohort. Immunohistochemical analysis of the tissue microarray showed that tumor PD-L1 expression was positively linked to HIF-1α expression, pro-tumor immunocyte infiltration and poor survival in HCC patients. Conclusion: This study provides evidence supporting the correlation between hypoxic signals and immunosuppression in HCC; the combined use of them might improve survival prediction and act as a potential predictor for PD-1/PD-L1 therapy.

Keywords: CD68+ macrophages; CD8+ T cells; HCC; HIF-1α; PD-L1; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen / genetics
  • B7-H1 Antigen / metabolism
  • Carcinoma, Hepatocellular* / genetics
  • Humans
  • Hypoxia / metabolism
  • Immunosuppression Therapy
  • Liver Neoplasms* / genetics
  • Prognosis
  • Retrospective Studies

Substances

  • B7-H1 Antigen